Provided By GlobeNewswire
Last update: Aug 14, 2024
- First patient treated in May for liver metastases from colorectal cancer -
- Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to-treat superficial cancers, with an overall response rate of almost 100% in treated lesions, no moderate or severe long-term toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% -
Read more at globenewswire.comNASDAQ:DRTS (6/26/2025, 6:08:57 PM)
3.015
+0.02 (+0.5%)
NASDAQ:DRTSW (6/26/2025, 4:30:01 PM)
0.2498
0 (-0.04%)
Find more stocks in the Stock Screener